IS7043A - Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu - Google Patents

Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu

Info

Publication number
IS7043A
IS7043A IS7043A IS7043A IS7043A IS 7043 A IS7043 A IS 7043A IS 7043 A IS7043 A IS 7043A IS 7043 A IS7043 A IS 7043A IS 7043 A IS7043 A IS 7043A
Authority
IS
Iceland
Prior art keywords
lungs
administration
chemically transformed
insulin
transformed insulin
Prior art date
Application number
IS7043A
Other languages
English (en)
Inventor
S. Patton John
Kuo Mei-Chang
Milton Harris J.
Leach Chester
Perkins Kimberly
Bueche Blaine
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of IS7043A publication Critical patent/IS7043A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS7043A 2001-05-21 2003-11-19 Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu IS7043A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29242301P 2001-05-21 2001-05-21
PCT/US2002/016464 WO2002094200A2 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin

Publications (1)

Publication Number Publication Date
IS7043A true IS7043A (is) 2003-11-19

Family

ID=23124608

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7043A IS7043A (is) 2001-05-21 2003-11-19 Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu

Country Status (35)

Country Link
US (3) US6838076B2 (is)
EP (1) EP1395294A4 (is)
JP (1) JP2004535401A (is)
KR (1) KR20030097876A (is)
CN (2) CN1314445C (is)
AP (1) AP1763A (is)
AR (1) AR033903A1 (is)
AU (1) AU2002303869B2 (is)
BG (1) BG108494A (is)
BR (1) BR0209896A (is)
CA (1) CA2447236A1 (is)
CO (1) CO5540371A2 (is)
CZ (1) CZ20033182A3 (is)
EA (1) EA007408B1 (is)
EC (1) ECSP034855A (is)
GE (1) GEP20063917B (is)
HR (1) HRP20030949A2 (is)
HU (1) HUP0400442A2 (is)
IL (2) IL158862A0 (is)
IS (1) IS7043A (is)
LT (1) LT5153B (is)
LV (1) LV13197B (is)
MA (1) MA26185A1 (is)
MX (1) MXPA03010649A (is)
MY (1) MY137181A (is)
NO (1) NO20035157D0 (is)
NZ (1) NZ529572A (is)
OA (1) OA13136A (is)
PL (1) PL366911A1 (is)
SK (1) SK15532003A3 (is)
TN (1) TNSN03116A1 (is)
TR (1) TR200400295T2 (is)
WO (1) WO2002094200A2 (is)
YU (1) YU98503A (is)
ZA (1) ZA200309085B (is)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2002303869B2 (en) * 2001-05-21 2007-08-16 Novartis Ag Pulmonary administration of chemically modified insulin
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
CA2470520A1 (en) * 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
KR101085375B1 (ko) * 2003-02-26 2011-11-21 넥타르 테라퓨틱스 중합체-인자 ⅷ 부분 콘쥬게이트
US9040664B2 (en) * 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
ES2447423T3 (es) 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
GB0328629D0 (en) * 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
PL1773878T3 (pl) * 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
US20060046852A1 (en) * 2004-08-26 2006-03-02 Rowe Richard E Wide area gaming system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8245758B2 (en) * 2006-10-30 2012-08-21 GM Global Technology Operations LLC Coulomb damped disc brake rotor and method of manufacturing
US20080206342A1 (en) * 2005-01-10 2008-08-28 Rosemary Kovelesky Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin
US20090036353A1 (en) * 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1863840A1 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
US20060271011A1 (en) * 2005-05-25 2006-11-30 Mock Bradley D Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced
JP5167133B2 (ja) * 2005-09-14 2013-03-21 マンカインド コーポレイション 結晶性微粒子表面に対する活性薬剤の親和性の増大に基づく薬物処方の方法
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20070124218A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US20070190127A1 (en) 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070292404A1 (en) * 2006-03-27 2007-12-20 Biosynexus Incorporated Antimicrobial polymer conjugates
EP2044097A4 (en) 2006-06-23 2010-10-06 Quintessence Biosciences Inc MODIFIED RIBONUCLEASES
DE602006016765D1 (de) * 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
AU2007281998B2 (en) * 2006-08-04 2014-02-20 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US8110655B2 (en) 2006-11-13 2012-02-07 Auxagen, Inc. Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
WO2008084051A1 (en) * 2007-01-12 2008-07-17 Novo Nordisk A/S Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINS AND COMPOSITIONS CONTAINING THEREOF
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US8633152B2 (en) * 2007-08-07 2014-01-21 Nanomaterials Technology Pte Ltd Process for making micro-sized protein particles
WO2009029656A1 (en) * 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
US8642532B2 (en) * 2007-11-16 2014-02-04 Guohan Yang Excipients for protein stabilization
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PL2910570T3 (pl) 2008-03-18 2017-06-30 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
KR101672684B1 (ko) 2008-06-13 2016-11-03 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8488661B2 (en) * 2008-06-13 2013-07-16 Verizon Patent And Licensing Inc. Systems and methods for data streaming
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US8029782B2 (en) 2008-10-01 2011-10-04 Quintessence Biosciences, Inc. Therapeutic ribonucleases
SI2379511T1 (sl) 2008-12-29 2015-03-31 Mannkind Corporation Substituirani diketopiperazinski analogi za uporabo kot sredstva za dostavo zdravil
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
BRPI1013154B1 (pt) 2009-06-12 2020-04-07 Mannkind Corp Micropartículas de dicetopiperazina com áreas de superfície específicas definidas, pó seco compreendendo as referidas micropartículas, método para formação das referidasmicropartículas e formação de micropartículas de fumaril diacetopiperazina, uso das referidas micropartículas e sistema de inalação
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
US9265723B2 (en) * 2009-07-31 2016-02-23 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
WO2011059609A2 (en) 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP2516664B1 (en) 2009-12-21 2015-07-22 Pharmathene Inc. Recombinant butyrylcholinesterases and truncates thereof
LT3459564T (lt) 2010-01-06 2022-03-10 Takeda Pharmaceutical Company Limited Plazmos kalikreiną surišantys baltymai
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
BR112013017080A8 (pt) 2011-01-06 2023-05-09 Dyax Corp Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
JP2014509603A (ja) * 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス システイン置換を含むヒトインスリン類似体およびヒトインスリン誘導体
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送***和方法
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
AU2014318579A1 (en) 2013-09-13 2016-04-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
PL3226888T3 (pl) 2014-12-01 2021-11-02 Ferring B.V. Podawanie selektywnego transsygnałowego inhibitora IL-6
KR20180094028A (ko) 2015-12-11 2018-08-22 다이액스 코포레이션 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
US10821156B2 (en) 2016-04-12 2020-11-03 Cell and Molecular Tissue Engineering, LLC Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site
AU2017355252A1 (en) * 2016-11-02 2019-06-06 Dow Global Technologies Llc Solid non-aqueous gel air odorizer
RU2758367C2 (ru) 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
DOP1982004086A (es) 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US4654324A (en) 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
EP0400472B1 (en) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5889153A (en) * 1994-05-20 1999-03-30 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, method for producing the same and intermediate compound therefor
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19628143A1 (de) 1996-07-12 1998-01-15 Basf Ag Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
DE69815877T2 (de) 1997-10-24 2004-05-19 Novo Nordisk A/S Aggregate von menschlichen insulinderivaten
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
CA2338419C (en) 1998-07-27 2011-06-14 Emisphere Technologies, Inc. Pulmonary delivery of active agents
CN1329502A (zh) * 1998-12-04 2002-01-02 普罗瓦利斯英国有限公司 含有胰岛素的药物组合物
NZ512581A (en) 1999-01-08 2002-12-20 Univ Virginia Commonwealth Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
CA2445494A1 (en) 2001-05-11 2002-11-21 Aradigm Corporation Optimization of the molecular properties and formulation of proteins delivered by inhalation
AU2002303869B2 (en) * 2001-05-21 2007-08-16 Novartis Ag Pulmonary administration of chemically modified insulin
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ES2307779T3 (es) * 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.

Also Published As

Publication number Publication date
IL158862A0 (en) 2004-05-12
NZ529572A (en) 2006-02-24
CA2447236A1 (en) 2002-11-28
EP1395294A4 (en) 2006-01-11
LV13197B (en) 2004-10-20
NO20035157D0 (no) 2003-11-20
OA13136A (en) 2006-12-13
YU98503A (sh) 2006-05-25
MA26185A1 (fr) 2004-07-01
JP2004535401A (ja) 2004-11-25
BG108494A (en) 2004-07-30
CN1582171A (zh) 2005-02-16
AU2002303869B2 (en) 2007-08-16
AP2003002918A0 (en) 2003-12-31
HRP20030949A2 (en) 2005-04-30
KR20030097876A (ko) 2003-12-31
EA007408B1 (ru) 2006-10-27
HUP0400442A2 (hu) 2005-03-29
WO2002094200A3 (en) 2003-02-20
EA200301222A1 (ru) 2004-08-26
ECSP034855A (es) 2004-03-23
ZA200309085B (en) 2004-11-22
CO5540371A2 (es) 2005-07-29
IL158862A (en) 2008-07-08
US20050152848A1 (en) 2005-07-14
BR0209896A (pt) 2004-08-17
US20030216542A1 (en) 2003-11-20
US20030118510A1 (en) 2003-06-26
US6838076B2 (en) 2005-01-04
LT2003107A (en) 2004-05-25
TR200400295T2 (tr) 2005-04-21
WO2002094200A2 (en) 2002-11-28
AR033903A1 (es) 2004-01-07
MXPA03010649A (es) 2005-10-05
CZ20033182A3 (cs) 2004-09-15
SK15532003A3 (sk) 2004-06-08
CN1314445C (zh) 2007-05-09
MY137181A (en) 2009-01-30
PL366911A1 (en) 2005-02-07
EP1395294A2 (en) 2004-03-10
US6890518B2 (en) 2005-05-10
GEP20063917B (en) 2006-09-11
AP1763A (en) 2007-08-02
TNSN03116A1 (en) 2005-12-23
LT5153B (lt) 2004-08-25
CN101045166A (zh) 2007-10-03

Similar Documents

Publication Publication Date Title
IS7043A (is) Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
DK3210637T3 (da) Infusionssæt
DK1383560T4 (da) Infusionssæt
EP1438086A4 (en) NOSE NEEDLE
ATE319666T1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
TWI315201B (en) Acidic insulin preparations having improved stability
DE60115418D1 (de) Mikroinfusionsvorrichtung zur verabreichung von medikamenten
CY2009013I1 (el) Νεα χρηση μιας ενωσης πεπτιδικης κατηγοριας για τη θεραπεια του μη νευροπαθους φλεγμονωδους πονου
DE60212066D1 (de) Abgabespritze
EE05020B1 (et) Glburiidi ravimkoostis
DE50209245D1 (de) Neuroprotektives medikament
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
DE60231611D1 (de) Verabreichung von opioiden durch inhalation
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
AU2002308889A1 (en) Novel heterocyclic compound and medicinal use thereof
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
ATA8202001A (de) Medikamentenapplikator
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DE10295185D2 (de) Anästhesiespritze
DE60228703D1 (de) Verabreichung von sedativa-hypnotika durch inhalation